• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Syndax Pharmaceuticals (SNDX)

Common Shares
Sell: $20.70|Buy: $21.40|Change: 0.54 (2.67%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Address

35 Gatehouse Drive
Building D, Floor 3
Waltham
MA
USA
02451

Telephone

+1 781 419-1400

Website

https://www.syndax.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Syndax Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-11-03T16:30:00
Syndax Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-11-03T00:00:00
Syndax Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-08-04T16:30:00
Syndax Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-08-04T00:00:00
Syndax Pharmaceuticals Inc Annual General Meeting for 20262026-05-14T08:30:00
Syndax Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-05T16:30:00
Syndax Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-05T00:00:00
Syndax Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-03-03T08:00:00
Syndax Pharmaceuticals Inc Annual Report for 20252026-03-03T00:00:00
Syndax Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252026-03-03T00:00:00
Syndax ASH 2025 Investor Event2025-12-08T07:00:00
8th Annual Evercore Healthcare Conference2025-12-04T11:15:00

Previous key dates

NameKey Date
Syndax ASH 2025 Investor Event2025-12-08T07:00:00
8th Annual Evercore Healthcare Conference2025-12-04T11:15:00
Jefferies 2025 London Healthcare Conference2025-11-20T05:00:00
Stifel 2025 Healthcare Conference2025-11-13T10:00:00
Guggenheim Second Annual Healthcare Innovation Conference2025-11-11T15:00:00
UBS Global Healthcare Conference 20252025-11-10T11:00:00
Syndax Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-03T16:30:00
Syndax Pharmaceuticals Inc Third Quarter Earnings Result for 20252025-11-03T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T09:00:00
Citi's 2025 BioPharma Back to School Conference2025-09-02T16:45:00
Syndax Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-08-04T16:30:00
Syndax Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-08-04T00:00:00
TD Cowen 6th Annual Oncology Innovation Summit2025-05-28T10:30:00
Bank of America Merrill Lynch Vegas Health Care Conference2025-05-15T12:20:00
Syndax Pharmaceuticals Inc Annual General Meeting for 20252025-05-14T08:30:00
Syndax Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-05T16:30:00
Syndax Pharmaceuticals Inc First Quarter Earnings Result for 20252025-05-05T00:00:00
Stifel 2025 Virtual Targeted Oncology Forum2025-04-09T10:30:00
Barclays 27th Annual Global Healthcare Conference2025-03-13T08:30:00
TD Cowen 45th Annual Health Care Conference2025-03-04T15:10:00
Syndax Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-03-03T08:00:00
Syndax Pharmaceuticals Inc Annual Report for 20242025-03-03T00:00:00
Syndax Pharmaceuticals Inc Fourth Quarter Earnings Result for 20242025-03-03T00:00:00
Citi's 2025 Virtual Oncology Leadership Summit2025-02-19T09:00:00
Guggenheim SMID Cap Biotech Conference2025-02-06T10:30:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-14T10:30:00
Syndax ASH 2024 Investor Event2024-12-09T10:00:00
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference2024-12-05T11:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.